Carroucell

Executive Summary

Carroucell, a Paris-based private biotech founded in 2016, leverages proprietary sol-gel technology to develop innovative solutions for cell and gene therapy applications. The company was founded by Dr. Tarek Fathallah, who discovered unique properties of sol-gel materials that can encapsulate and protect therapeutic cells or genetic material, potentially improving stability and delivery. Carroucell’s technology aims to address key challenges in regenerative medicine and cell therapy, such as cell viability during storage and administration. The company's platform has the potential to enable more efficient manufacturing and better outcomes for patients, positioning it as a promising player in the rapidly evolving cell and gene therapy landscape. However, as a private entity with limited public information, Carroucell's progress and financial standing are not fully transparent.

Upcoming Catalysts (preview)

• TBDSeries A Funding Announcement60% success
• TBDPartnership with a Major Pharma/CRO40% success
• TBDPreclinical Proof-of-Concept Data Release50% success